VLA15, a new global Lyme disease vaccine undergoes clinical trials

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60077344%3A_____%2F23%3A00577347" target="_blank" >RIV/60077344:_____/23:00577347 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S1473309923003122?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1473309923003122?via%3Dihub</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

VLA15, a new global Lyme disease vaccine undergoes clinical trials

Popis výsledku v původním jazyce

Lyme disease (Lyme borreliosis) is a tick-borne bacterial infection that occurs in the temperate climates of North America and Eurasia. Treatment with antibiotics is effective only in the early stages of infection. Although the first human Lyme disease vaccine (LYMErix by SmithKline Beecham, Pittsburgh, PA, USA) was marketed and distributed in the USA from 1998 until 2002, it was discontinued and no vaccine is currently available.1, 2, 3 In The Lancet Infectious Diseases, Nicole Bézay and colleagues report the results of a randomised, phase 1, clinical trial in healthy adults immunised with Valneva's novel, multivalent outer surface protein A (OspA) subunit vaccine called VLA15.4

Název v anglickém jazyce

VLA15, a new global Lyme disease vaccine undergoes clinical trials

Popis výsledku anglicky

Lyme disease (Lyme borreliosis) is a tick-borne bacterial infection that occurs in the temperate climates of North America and Eurasia. Treatment with antibiotics is effective only in the early stages of infection. Although the first human Lyme disease vaccine (LYMErix by SmithKline Beecham, Pittsburgh, PA, USA) was marketed and distributed in the USA from 1998 until 2002, it was discontinued and no vaccine is currently available.1, 2, 3 In The Lancet Infectious Diseases, Nicole Bézay and colleagues report the results of a randomised, phase 1, clinical trial in healthy adults immunised with Valneva's novel, multivalent outer surface protein A (OspA) subunit vaccine called VLA15.4

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30303 - Infectious Diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů